Comparison of the Time to Recurrence Between Ranibizumab and Aflibercept

Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD

NCT01958918 ·Status: COMPLETED ·Phase: PHASE4

Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab

NCT02309281 ·Status: COMPLETED ·Phase: PHASE4

Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD

NCT01948830 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration

NCT01780935 ·Status: COMPLETED ·Phase: PHASE3

Aflibercept in Recurrent or Persistent CNV

NCT02669953 ·Status: RECRUITING

Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients.

NCT01942213 ·Status: COMPLETED

UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD)

NCT01988662 ·Status: COMPLETED ·Phase: PHASE4

Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye

NCT01986907 ·Status: COMPLETED ·Phase: PHASE4

Ranibizumab Treatment for Age-Related Macular Degeneretion

NCT02158624 ·Status: UNKNOWN ·Phase: NA

A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.

NCT02034006 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

NCT01217944 ·Status: COMPLETED ·Phase: PHASE3

To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema

NCT01846299 ·Status: COMPLETED ·Phase: PHASE3

The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration

NCT00857259 ·Status: TERMINATED ·Phase: PHASE2

Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration

NCT00284089 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.

NCT01840410 ·Status: COMPLETED ·Phase: PHASE3

Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab

NCT00559715 ·Status: UNKNOWN ·Phase: PHASE3

Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration

NCT02398500 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)

NCT05110209 ·Status: COMPLETED

Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen

NCT02274259 ·Status: COMPLETED ·Phase: PHASE4

Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration

NCT02140151 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

NCT02258009 ·Status: WITHDRAWN ·Phase: PHASE4

A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy.

NCT02174211 ·Status: COMPLETED ·Phase: NA

Analysis of naïve Patients With Age-related Macular Degeneration Neovascular Type and Treated With Ranibizumab (Lucentis®) in Treat-and-extend at the CHU Brugmann.

NCT04988178 ·Status: COMPLETED

Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration

NCT00288561 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration

NCT02611778 ·Status: COMPLETED ·Phase: PHASE3